GL Pharm Tech Corp. (KOSDAQ:204840)

Market Cap	98.13B
Revenue (ttm)	28.05B
Net Income (ttm)	-680.77M
Shares Out	76.97M
EPS (ttm)	-8.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,544
Average Volume	243,395
Open	1,204.00
Previous Close	1,204.00
Day's Range	1,180.00 - 1,221.00
52-Week Range	900.00 - 1,844.00
Beta	1.01
RSI	37.35
Earnings Date	Aug 12, 2025

About GL Pharm Tech

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 27
• Stock Exchange: KOSDAQ
• Ticker Symbol: 204840

Financial Performance

In 2024, GL Pharm Tech's revenue was 26.05 billion, an increase of 0.06% compared to the previous year's 26.03 billion. Losses were -2.34 billion, -37.64% less than in 2023.